ECA39 is a novel distant metastasis-related biomarker in colorectal cancer

World Journal of Gastroenterology

Volumn 12, Issue 36, 2006, Pages 5884-5889

  Yoshikawa, Reigetsu ^a   Yanagi, Hidenori ^a   Shen, Chun Shen ^a   Fujiwara, Yoshinori ^a   Noda, Masafumi ^a   Yagyu, Toshihiko ^a   Gega, Makoto ^a   Oshima, Tsutomu ^a   Yamamura, Takehira ^a   Okamura, Haruki ^a   Nakano, Yoshiro ^a   Morinaga, Tomori ^a   Hashimoto Tamaoki, Tomoko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Distant metastasis; ECA39; Integrated medicine; Polysaccharide K

Indexed keywords

BIOLOGICAL MARKER; KRESTIN; MUTANT PROTEIN; MYC PROTEIN; PROTEIN ECA39; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER TISSUE; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HETEROZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RELIABILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 33750136864     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i36.5884     Document Type: Article

References (33)

1. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jernal A, Ward E, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95: 1276-1299
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33
3. Yanagi H, Noda M. Yoshikawa R, Ikeuchi H, Gega M, Yamamura T, Kusunoki M. Randomized clinical trial of pharmacokinetic modulating chemotherapy (PMC) in combination with continuous 5-FU infusion plus oral UFT for adjuvant chemotherapy after curative resection for Dukes' C colorectal cancer patients. Proc Am Soc Clin Oncol 2003; 22: 293
4. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001; 61: 1029-1037
5. Kusunoki M, Yanagi H, Noda M, Yoshikawa R, Yamamura T. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 2000; 89: 1228-1235
6. Gega M, Yanagi H, Noda M, Yoshikawa R, Yamamura T. Postoperative follow-up of tumor markers once a month is beneficial to the colorectal cancer patients with pharmacokinetic modulating chemotherapy treatment. Proc Am Soc Clin Oncol 2003; 22: 329
7. Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T. Use of complementary alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 2000; 18: 2515-2521
8. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 2005; 23: 2645-2654
9. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994; 343: 1122-1126
10. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T, Morishita Y. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004; 90: 1003-1010
11. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 1995; 18:216-222
12. Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Nakamoto S, Kawashima M, Niibe H. Effect of Krestin as adjuvant treatment following radical radiotherapy in non-small cell lung cancer patients. Cancer Detect Prev 1997; 21: 71-77
13. Hirose K, Zachariae CO, Oppenheim JJ, Matsushima K: Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 1990; 9: 475-483
14. Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Imai S, Tobe T. In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 1991; 32:335-341
15. Noguchi K, Tanimura H, Yamaue H, Tsunoda T, Iwahashi M, Tani M, Mizobata S, Hotta T, Arii K, Tamai M. Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro. Anticancer Res 1995; 15: 255-258
16. Ehrke MJ, Reino JM, Eppolito C, Mihich E. The effect of PS-K, a protein bound polysaccharide, on immune responses against allogeneic antigens. Int J Immunopharmacol 1983; 5: 35-42
17. Hosokawa M, Mizukoshi T, Morikawa K, Xu ZY, Kobayashi H. The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites. Cancer Immunol Immunother 1986; 22: 181-185
18. Yoshikawa R, Yanagi H, Hashimoto-Tamaoki T, Morinaga T, Nakano Y, Noda M, Fujiwara Y, Okamura H, Yamamura T. Gene expression in response to anti-tumour intervention by polysaccharide-K (PSK) in colorectal carcinoma cells. Oncol Rep 2004;12: 1287-1293
19. Goh HS, Chan CS, Khine K, Smith DR. p53 and behaviour of colorectal cancer. Lancet 1994; 344: 233-234
20. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ, Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106: 42-48
21. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
22. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002; 99: 9433-9438
23. Niwa O, Kumazaki T, Tsukiyama T, Soma G, Miyajima N, Yokoro K. A cDNA clone overexpressed and amplified in a mouse teratocarcinoma line. Nucleic Acids Res 1990; 18: 6709
24. Benvenisty N, Leder A, Kuo A, Leder P. An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence. Genes Dev 1992; 6:2513-2523
25. Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, Benvenisty N. ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc Natl Acad Sci USA 1996; 93: 7143-7148
26. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90: 7804-7808
27. Wagner AJ, Meyers C, Laimins LA, Hay N. c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ 1993; 4: 879-883
28. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 1993; 4:57-65
29. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996; 382: 511-517
30. Prochownik EV. c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther 2004; 4: 289-302
31. Eden A, Simchen G, Benvenisty N. Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. J Biol Chem 1996; 271: 20242-20245
32. O'Dwyer PJ, Stevenson JP. Chemotherapy of advanced colorectal cancer. In: Benson AL, ed. Gastrointestinal Oncology, Cancer Treatment and Research. Norwell: Kluwer Academic Publishers, 1998: 111-152
33. Arango D, Mariadason JM, Wilson AJ, Yang W, Comer GA, Nicholas C, Aranes MJ, Augenlicht LH. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003; 89: 1757-1765